AbbVie is wading into the waters of psychedelics, penning a pact with Gilgamesh Pharmaceuticals aimed at developing next-gen ...

Takeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has still found $100 million to ...

OnKure Therapeutics has merged with Reneo Pharmaceuticals, jumping onto Wall Street with $120 million and a lead breast ...

Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug ...

The emerging field of pulsed field ablation continues to pick up speed around the globe, with Medtronic collecting a ...

Merck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high rate of discontinuations ...

Guardant Health has its sights set on redefining how people get checked for colorectal cancer, and its blood test for catching stray tumor DNA soon has a date with the FDA. The agency has scheduled an ...

Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore O’Neill—himself an alum of the ...

Sanofi Chief Scientific Officer and Head of Research Frank Nestle, M.D., is leaving the company. | Sanofi CSO Frank Nestle is ...

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking industry layoffs. Last year, we tallied 187 total layoffs ...

One of Johnson & Johnson’s medical device subsidiaries is pulling one of its pediatric electrosurgery devices from the market ...

Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart ...